我是 LongbridgeAI，我可以總結文章信息。Regenxbio (RGNX) 定於 8 月 6 日市場開盤前公佈 2026 年第二季度財報。共識預期每股收益（EPS）為-0.11 美元，收入為 9646 萬美元，同比增長 352.9%。分析師情緒近期轉為負面，過去三個月 EPS 預期經歷了一次上調和三次下調，而收入預期則經歷了五次下調，沒有上調
Regenxbio (RGNX) is scheduled to announce Q2 earnings results on Thursday, August 6th, before market open. The consensus EPS Estimate is -$0.11 and the consensus Revenue Estimate is $96.46M (+352.9% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 3 downward. Revenue estimates have seen 0 upward revisions and 5 downward. ...